
ImmPACT Bio: Innovating transformative CAR-T cell therapies for advanced cancer patients.
Founded with a mission to revolutionize cancer treatment, ImmPACT Bio focuses on developing transformative CAR-T cell therapies for patients with advanced cancer who have exhausted other treatment options. The company's vision is to harness cutting-edge science to create life-saving treatments. ImmPACT Bio offers a pipeline of innovative therapies, including CD19/20 bispecific and TGF-β targeted treatments, aimed at improving patient outcomes in the oncology market.
Notable figures associated with ImmPACT Bio include leading scientists and industry experts who drive its research and development efforts. The company has attracted significant investment from prominent venture capital firms, underscoring confidence in its potential. ImmPACT Bio's key achievements include advancing multiple therapies into clinical trials, demonstrating promising results in early studies, and establishing strategic partnerships. Its impact lies in offering new hope to cancer patients through pioneering CAR-T cell therapies.

AffyImmune Therapeutics
affyimmune.com

A2 Biotherapeutics
a2bio.com

Inceptor Bio
inceptor.bio

INmune Bio
inmunebio.com

Cartography Biosciences
cartography.bio

Outpace Bio
outpacebio.com

ImmunoGenesis
immunogenesis.com

Tactiva Therapeutics

ImmunityBio
immunitybio.com

Iovance Biotherapeutics
iovance.com

Cell BioEngines
cellbioengines.com

Chimera Bioengineering
chimera.bio

3T Biosciences
3tbiosciences.com

Cellective BioTherapy

Aleta Biotherapeutics
aletabio.com
Companies similar to Immpact Bio include AffyImmune Therapeutics, A2 Biotherapeutics, Inceptor Bio and INmune Bio.
Immpact Bio was founded in 2017.
Immpact Bio's headquarters is located in Camarillo, CA, US.
Immpact Bio's most recent funding round was for $111M (USD) in January 2022.
As of Jan 20, 2022, Immpact Bio has raised a total of $129M (USD).
Immpact Bio has 105 employees as of Feb 5, 2024.